Nassif David W.

SEC source: 0001193125-26-398678 · ownership.xml · nonDerivative · entry 2

Nassif David W. · CIK 0001636975 · CFO / CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,800

F2 · kind: Gift to charitable organization.

SEC source: 0001193125-26-398678 · ownership.xml · nonDerivative · entry 1

Nassif David W. · CIK 0001636975 · CFO / CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,300

F1 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions at prices ranging from $36.30 to $36.71 per share. The shares sold were acquired upon vesting of restricted stock units on various dates. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001193125-26-239720 · ownership.xml · nonDerivative · entry 1

Nassif David W. · CIK 0001636975 · CFO / CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,300

F1 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions at prices ranging from $30.08 to $30.55 per share. The shares sold were acquired upon vesting of restricted stock units on various dates. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F2 · balance_after: The total number of shares beneficially owned previously reported in the Form 3 filed on March 18, 2026 was understated by 6,375 shares due to an administrative error in the number of shares reported as withheld for tax obligations in connection with an RSU vesting transaction. This filing reflects the corrected beneficial ownership amount.

SEC source: 0001636050-22-000020 · wf-form4_164453070649941.xml · derivative · entry 1

Nassif David W. · CIK 0001636975 · Director · Interim CEO, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 546,500

Underlying: Common Stock · 546,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: One-third of the restricted stock units shall vest on February 8, 2023, February 8, 2024 and February 8, 2025, subject to the Reporting Person providing continuous service to the Issuer through each such date.

F2 · derivative.expiration_date: One-third of the restricted stock units shall vest on February 8, 2023, February 8, 2024 and February 8, 2025, subject to the Reporting Person providing continuous service to the Issuer through each such date.

SEC source: 0001636050-21-000099 · wf-form4_163909267819349.xml · derivative · entry 3

Nassif David W. · CIK 0001636975 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,066

Underlying: Common Stock · 17,534 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on April 15, 2021 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.

F3 · derivative.exercise_date: 50% of the shares of common stock underlying the remaining restricted stock units vest on April 15, 2022 and the remainder vest on April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date.

F3 · derivative.expiration_date: 50% of the shares of common stock underlying the remaining restricted stock units vest on April 15, 2022 and the remainder vest on April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date.

SEC source: 0001636050-21-000099 · wf-form4_163909267819349.xml · nonDerivative · entry 2

Nassif David W. · CIK 0001636975 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,244

F1 · shares: The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units.

SEC source: 0001636050-21-000099 · wf-form4_163909267819349.xml · nonDerivative · entry 1

Nassif David W. · CIK 0001636975 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,538

SEC source: 0001636050-21-000046 · wf-form4_161886561553902.xml · derivative · entry 1

Nassif David W. · CIK 0001636975 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 239,000

Underlying: Common Stock · 239,000 shares

Expires 2031-04-14

F1 · derivative.exercise_date: The option vests over a period of three years with one-third of the shares of common stock underlying the option vesting on April 15, 2022 and the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan.

SEC source: 0001636050-21-000031 · wf-form4_161646271888893.xml · derivative · entry 2

Nassif David W. · CIK 0001636975 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,060 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on July 31, 2020 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.

F1 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on July 31, 2020 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.

F1 · derivative.expiration_date: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on July 31, 2020 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.

SEC source: 0001636050-21-000031 · wf-form4_161646271888893.xml · nonDerivative · entry 1

Nassif David W. · CIK 0001636975 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,004

SEC source: 0001209191-20-036808 · doc4.xml · derivative · entry 3

Nassif David W. · CIK 0001636975 · Principal Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,060

Underlying: Common Shares · 15,060 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. 50% of the common shares underlying the restricted stock units vested on January 31, 2020 but settlement of such portion of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.

F3 · derivative.expiration_date: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. 50% of the common shares underlying the restricted stock units vested on January 31, 2020 but settlement of such portion of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.

SEC source: 0001209191-20-036808 · doc4.xml · nonDerivative · entry 2

Nassif David W. · CIK 0001636975 · Principal Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,944

F1 · balance_after: Balance includes 9,150 shares of Common Stock owned by the reporting person prior to his appointment as a Section 16 officer but was not previously reported.

SEC source: 0001209191-20-036808 · doc4.xml · nonDerivative · entry 1

Nassif David W. · CIK 0001636975 · Principal Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,210

F1 · balance_after: Balance includes 9,150 shares of Common Stock owned by the reporting person prior to his appointment as a Section 16 officer but was not previously reported.

SEC source: 0001209191-20-025016 · doc4.xml · derivative · entry 2

Nassif David W. · CIK 0001636975 · Principal Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,600

Underlying: Common Shares · 52,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: One-third of the common shares underlying the restricted stock unit shall vest on April 15, 2021, April 15, 2022 and April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date.

F3 · derivative.expiration_date: One-third of the common shares underlying the restricted stock unit shall vest on April 15, 2021, April 15, 2022 and April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date.

SEC source: 0001209191-20-025016 · doc4.xml · derivative · entry 1

Nassif David W. · CIK 0001636975 · Principal Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,900

Underlying: Common Shares · 78,900 shares

Expires 2030-04-14

F1 · derivative.exercise_date: The option vests over a period of four years with 25% of the common shares underlying the option vesting on April 15, 2021 and the remainder vesting in 12 equal quarterly installments thereafter, subject to Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

SEC source: 0001636050-19-000085 · wf-form4_156935969903570.xml · derivative · entry 1

Nassif David W. · CIK 0001636975 · Principal Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,120

Underlying: Common Shares · 30,120 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date.

F2 · derivative.expiration_date: 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date.

SEC source: 0001209191-19-040520 · doc4.xml · derivative · entry 2

Nassif David W. · CIK 0001636975 · Principal Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Shares · 75,000 shares

Expires 2029-06-30

F2 · derivative.exercise_date: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

F3 · derivative.exercise_date: One-third of the option will vest at such time as the Issuer's 30-day trailing volume weighted average closing stock price ("30-day VWAP") is equal to $12.84; one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $25.68; and one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $38.52, in each case subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0001209191-19-040520 · doc4.xml · derivative · entry 1

Nassif David W. · CIK 0001636975 · Principal Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Shares · 150,000 shares

Expires 2029-06-30

F1 · derivative.exercise_date: The option vests over a period of four years, with 25% of the common shares underlying the option vesting on July 1, 2020 and the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date.

F2 · derivative.exercise_date: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

SEC source: 0001209191-18-049373 · doc4.xml · derivative · entry 6

Nassif David W. · CIK 0001636975 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 15,987 shares

Expires 2027-12-28

F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

F2 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

SEC source: 0001209191-18-049373 · doc4.xml · derivative · entry 5

Nassif David W. · CIK 0001636975 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 20,000 shares

Expires 2026-06-17

F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

F2 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

SEC source: 0001209191-18-049373 · doc4.xml · derivative · entry 4

Nassif David W. · CIK 0001636975 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 51,832 shares

Expires 2022-01-25

F3 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time.

F3 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time.

SEC source: 0001209191-18-049373 · doc4.xml · derivative · entry 3

Nassif David W. · CIK 0001636975 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 159,642 shares

Expires 2020-05-01

F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

F2 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

SEC source: 0001209191-18-049373 · doc4.xml · derivative · entry 2

Nassif David W. · CIK 0001636975 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,100 shares

Expires 2019-07-19

F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

F2 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

SEC source: 0001209191-18-049373 · doc4.xml · nonDerivative · entry 1

Nassif David W. · CIK 0001636975 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding restricted share unit was converted into the right to receive (1) a cash payment equal to (x) $4.46, multiplied by (y) the total number of shares subject to such restricted share unit and (2) a number of CVRs equal to the total number of shares subject to such restricted share unit.

F1 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding restricted share unit was converted into the right to receive (1) a cash payment equal to (x) $4.46, multiplied by (y) the total number of shares subject to such restricted share unit and (2) a number of CVRs equal to the total number of shares subject to such restricted share unit.

SEC source: 0001562180-18-003255 · primarydocument.xml · nonDerivative · entry 1

Nassif David W. · CIK 0001636975 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,157

F1 · kind: Sales are pursuant to a 10b5-1 Plan.

SEC source: 0001104659-18-043809 · a4.xml · nonDerivative · entry 1

Nassif David W. · CIK 0001636975 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,314

F1 · kind: Sales are pursuant to a 10b5-1 Plan.

F2 · shares: Shares were sold to cover taxes.

SEC source: 0001209191-17-067562 · doc4.xml · derivative · entry 1

Nassif David W. · CIK 0001636975 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,987

Underlying: Ordinary Shares · 15,987 shares

Expires 2027-12-28

F1 · derivative.exercise_date: 1/3rd of the Option Shares shall vest on the first anniversary of the grant date. Thereafter, the remaining balance of the Option Shares shall vest in a series of 8 equal consecutive quarterly installments until fully vested.

SEC source: 0001209191-17-060965 · doc4.xml · nonDerivative · entry 1

Nassif David W. · CIK 0001636975 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,315

F1 · shares: Each restricted stock unit represents a contingent right to receive one share of SteadyMed Ltd. ordinary shares.

F2 · shares: RSU shall vest in two tranches. On June 30, 2018, 22,158 shall vest. Thereafter, on the date that the New Drug Application for Trevyent is approved by the U.S. Food and Drug Administration, the remaining balance of 22,157 shares shall vest.